Welcome to our dedicated page for Organogenesis Hldgs SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Organogenesis Holdings Inc. (ORGO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer, Organogenesis submits periodic and current reports that describe its financial condition, operating results, clinical programs, governance matters, and capital structure.
Through this page, users can review Form 10-K annual reports and Form 10-Q quarterly reports, which include audited or reviewed financial statements, segment information for its regenerative medicine operations, and detailed discussions of risk factors, research and development spending, and market dynamics for its Advanced Wound Care and Surgical & Sports Medicine product categories. These filings also outline how the company reports net product revenue, operating expenses, cash and cash equivalents, and information about Series A redeemable convertible preferred stock.
Current reports on Form 8-K document material events such as quarterly earnings releases, updates on the Phase 3 randomized controlled trials of ReNu for knee osteoarthritis, plans to request or initiate a Biologics License Application (BLA), and stockholder meeting results. For example, Organogenesis has used Form 8-K to furnish press releases on ReNu clinical data, to describe its intention to pursue a BLA submission pathway, and to report the outcomes of its annual meeting, including director elections and advisory votes on executive compensation.
Investors can also use this page to track governance and capital structure disclosures, including approvals related to the potential issuance of additional Class A common stock upon conversion of Series A Convertible Preferred Stock under Nasdaq listing rules. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify important financial metrics, clinical program updates, and regulatory milestones without reading every line of each report.
Organogenesis Holdings Inc. vice president of strategy Robert Cavorsi reported three tax-withholding dispositions of Class A Common Stock tied to equity compensation. On February 15, 2026, he delivered 6,667, 5,549 and 5,442 shares at $3.73 per share to cover tax obligations, and continued to hold a substantial direct stake afterward.
Organogenesis Holdings Inc. reported insider tax-related share dispositions by Chief Administrative and Legal Officer Lori Freedman. On
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported several tax-related share dispositions of Class A Common Stock. On February 15, 2026, he delivered an aggregate of 271,406 shares at
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow reported four tax-withholding dispositions of Class A common stock on February 15, 2026. The transactions, coded “F” and priced at
Organogenesis Holdings Inc. vice president of health policy Antonio S. Montecalvo reported four tax-withholding dispositions of Class A Common Stock on February 15, 2026. A total of 18,619 shares were delivered at
Organogenesis Holdings Inc.
The filing shows First Light Asset Management may be deemed to beneficially own 3,611,616 shares, representing 2.85% of Organogenesis’ common stock. Mathew P. Arens may be deemed to beneficially own 3,888,816 shares, or 3.06% of the class, including 231,000 shares he holds directly and additional shares through joint and advised accounts.
The reporting persons certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Organogenesis. Because each now reports ownership below 5% of the outstanding shares, the filing confirms they are no longer large (5%+) shareholders.
Organogenesis Holdings Inc. has a large shareholder group led by Soleus Capital reporting a significant passive stake. Through Soleus Capital Master Fund, L.P., the group beneficially owns 9,985,951 shares of common stock, representing 7.9% of the outstanding shares based on 126,912,142 shares outstanding as of October 30, 2025.
All reported shares are held directly by the Master Fund, with several Soleus-affiliated entities and Guy Levy listed because of their control roles. These parties expressly disclaim beneficial ownership outside their reporting obligations under U.S. securities law and certify the holdings were not acquired to change or influence control of Organogenesis.
Organogenesis Holdings Inc. reported an insider stock transaction by a company director. On 12/16/2025, the director sold 200,000 shares of Class A Common Stock in open-market trades at a weighted-average price of $5.1353 per share, with individual trade prices ranging from $5.10 to $5.24.
After this sale, the director directly beneficially owns 2,565,591 shares of Class A Common Stock. In addition, the director has indirect beneficial ownership through three trusts holding 918,680 shares, 7,928,570 shares, and 335,719 shares of Class A Common Stock, respectively.
Organogenesis Holdings Inc. reported Q3 2025 results showing stronger profitability. Total revenue was $150.864M (net product revenue $150.487M), up from $115.177M a year ago. Income from operations rose to $20.727M, and net income reached $21.567M, or $0.11 per diluted share. Advanced Wound Care drove the quarter with $141.451M, while Surgical & Sports Medicine contributed $9.036M.
Year to date, revenue was $338.562M versus $355.387M in 2024, with a net loss of $6.668M. Cash and cash equivalents were $63.745M and operating cash flow was an outflow of $49.729M for the nine months. Accounts receivable increased to $168.783M and inventories to $39.583M. The company recorded $0.603M of grant income tied to the Smithfield facility buildout and ended the quarter with deferred grant income on the balance sheet.
The revolving credit facility was reduced to $75M with updated covenants; there were no outstanding borrowings. Management flagged potential Medicare LCD changes effective January 1, 2026 that would limit coverage for several products. In clinical updates, a second Phase 3 ReNu knee OA trial did not meet its primary endpoint; an FDA meeting is scheduled for December 12, 2025 to discuss a BLA using combined data.
Organogenesis Holdings (ORGO) reported that it announced its fiscal third-quarter results for the period ended September 30, 2025, via a press release dated November 6, 2025. The company furnished the press release as Exhibit 99.1 to an 8-K.
The company stated that the press release is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. For full details, readers are directed to the furnished Exhibit 99.1.